Implications of nanotechnology for the treatment of cancer : Recent advances
Copyright © 2019 Elsevier Ltd. All rights reserved..
The use of nanoparticles dramatically increases the safety and efficacy of the most common anticancer drugs. The main advantages of nano-drugs and delivery systems based on nano-technology are effective targeting, delayed release, increased half-life, and less systemic toxicity. The use of nano-carriers has led to significant improvements in drug delivery to targets compared with traditional administration of these drugs. In this review, the main tendencies in nano-drug formulations as well as factors limiting their use in clinical settings are discussed. Additionally, the current status of approved nano-drugs for cancer treatment is reviewed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
Seminars in cancer biology - 69(2021) vom: 01. Feb., Seite 190-199 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Klochkov, Sergey G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 03.03.2022 Date Revised 03.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.semcancer.2019.08.028 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300556756 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300556756 | ||
| 003 | DE-627 | ||
| 005 | 20231225102758.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.semcancer.2019.08.028 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1001.xml |
| 035 | |a (DE-627)NLM300556756 | ||
| 035 | |a (NLM)31446004 | ||
| 035 | |a (PII)S1044-579X(19)30187-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Klochkov, Sergey G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Implications of nanotechnology for the treatment of cancer |b Recent advances |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.03.2022 | ||
| 500 | |a Date Revised 03.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Ltd. All rights reserved. | ||
| 520 | |a The use of nanoparticles dramatically increases the safety and efficacy of the most common anticancer drugs. The main advantages of nano-drugs and delivery systems based on nano-technology are effective targeting, delayed release, increased half-life, and less systemic toxicity. The use of nano-carriers has led to significant improvements in drug delivery to targets compared with traditional administration of these drugs. In this review, the main tendencies in nano-drug formulations as well as factors limiting their use in clinical settings are discussed. Additionally, the current status of approved nano-drugs for cancer treatment is reviewed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Drug delivery | |
| 650 | 4 | |a Nano-drugs | |
| 650 | 4 | |a Nano-technology | |
| 650 | 4 | |a Oncotarget | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Neganova, Margarita E |e verfasserin |4 aut | |
| 700 | 1 | |a Nikolenko, Vladimir N |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Kuo |e verfasserin |4 aut | |
| 700 | 1 | |a Somasundaram, Siva G |e verfasserin |4 aut | |
| 700 | 1 | |a Kirkland, Cecil E |e verfasserin |4 aut | |
| 700 | 1 | |a Aliev, Gjumrakch |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in cancer biology |d 1991 |g 69(2021) vom: 01. Feb., Seite 190-199 |w (DE-627)NLM012641944 |x 1096-3650 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2021 |g day:01 |g month:02 |g pages:190-199 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.semcancer.2019.08.028 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 69 |j 2021 |b 01 |c 02 |h 190-199 | ||